
Just one month after the US Food and Drug Administration (FDA) vouched for Biogen's drug Aduhelm for treating Alzheimer's disease, the authority has adjusted the prescribing information for this medication, which changes the patients that the drug should be recommended to.
Biogen took the initiative to this drug on the basis of conversations, which Biogen representatives have had with doctors after the approval.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app